Browsing by Author "Cerrahoǧlu L."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression
    (Cukurova Univ Tip Fakultesi Psikiyatri Anabilim Dali, 2008) Taşkin E.O.; Aydemir Ö.; Deveci A.; Taneli F.; Selçuki D.; Cerrahoǧlu L.; Danaci A.E.
    Objective: In this study, it is aimed to compare the level of Brain-Derived Neurotrophic Factor (BDNF) of patients with migraine and fibromyalgia to that of depressive patients and healthy subjects in order to answer the question whether stress is related to pain syndromes. Methods: In the migraine group 27 patients and in the fibromyalgia group 19 patients without any previous antidepressant treatment and psychiatric diagnosis were included. In the depression group, 24 patients with at least eight weeks of antidepressant-free period were invited to the study. In the depression group no co-morbid diagnosis in the first axis was made. Twenty-six subjects without any previous psychiatric diagnosis and psychiatric treatment consisted the control group. For making diagnosis of depression and other first axis disorders Structured Clinical Interview for DSM- IV (SCID-I) was used in all study groups. For the assessment of the severity of depression Hamilton Depression Rating Scale (HAM-D) was applied. The diagnosis of migraine was made according to the criteria of International Headache Society. For the diagnosis of the fibromyalgia the criteria of American College of Rheumatology was used. The severity of pain was assessed with visual analogue scale (VAS) in the migraine and fibromyalgia groups. Serum BDNF was kept at -70°C before testing, and assayed with an ELISA Kit (Promega; Madison, WI, USA), after dilution with the Block and Sample solution provided with the kit. The data were subjected to Kruskal Wallis Test in the comparison of serum BDNF levels. Results: The serum BDNF level of the depression group (21.2±11.3 ng/ml) was statistically lower (p<0.0001) than the level of the migraine group (32.2±10.1 ng/ml), fibromyalgia group (30.7±8.9 ng/ml) and the control group (31.4±8.8 ng/ml). The level of BDNF was not significantly different in the migraine, fibromyalgia and control groups. There was no significant correlation between serum BDNF levels, and age and gender. In pain syndromes there was no signification correlation between serum BDNF levels, and mean scores of HAM-D and VAS (r= 0.085; p= 0.579 and r= 0.191; p= 0.204 respectively). Similarly there was no significant correlation between serum BDNF levels and HAM-D scores in the depression group (r=0.122; p= 0.579). Conclusions: Even though the pain syndromes were suggested to be associated with stress, in this present work, serum BDNF level as one of the markers of stress does not support this hypothesis. This might be related to the factor that in pain syndromes such as fibromyalgia or migraine, serum BDNF level may be affected by the alteration in peripheral platelet functions. Furthermore in a limited chronic stress serum BDNF levels tend to be not affected and this may play a significant role in our results.
  • No Thumbnail Available
    Item
    Clinical and radiological characteristics of spondyloarthropathy; [Spondiloartropatili hastalarin klinik ve radyolojik özellikleri]
    (2008) Turan Y.; Duruöz M.T.; Cerrahoǧlu L.
    Objective: The objective of this study is to determine the clinical characteristics of patients with spondyloarthropaties (SpA). Patients and Methods: One hundred -twenty patients that match European Spondyloarthropaties Study Group (ESSG) diagnostic criteria, were included in this study. There were 48 ankylosing spondylitis (AS), 42 reactive arthritis (ReA), 9 psoriatic arthritis (PsA), 3 enteropathic arthritis (EA) and 18 undifferentiated SpA (uSpA) patients. Demographic data, clinical parameters and grade of sacroiliitis were assessed. Enthesitis were evaluated by the Mander Enthesis Index (MEI). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) evaluated disease activity and functional status in AS patients, respectively. Results: The most frequently seen symptom was night pain (55.1%) and the most frequently seen radiographic involvement was right sacroiliitis (95.8%), Epin calcanei was most frequently observed in PsA (55.5%) and EA (33.3%) patients. The incidence of enthesitis in patients with SpA was 86.7%. Uveitis and heel pain were most commonly found respectively in AS (16.7%), and ReA (47.6%) patients. Conclusion: Whereas patients with SpA had similar clinical symptoms, their most common complaint was night pain. We think that it should be keep in mind while medical treatment is put in order.
  • No Thumbnail Available
    Item
    Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study
    (Galenos Yayincilik,, 2012) Eskiyurt N.; Irdesel J.; Sepici V.; Uǧurlu H.; Kirazli Y.; Ardiç F.; Bütün B.; Akyüz G.; Cerrahoǧlu L.; Şendur Ö.F.; Yalçin P.; Öncel S.; Saridoǧan M.; Sarpel T.; Tosun M.; Kutsal Y.G.; Şenel K.; Gürsoy S.; Cantürk F.; Demir H.; Özdener F.; Öncel H.
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.
  • No Thumbnail Available
    Item
    Comparison of the efficacy of low-level laser therapy and pulsed ultrasound treatment in carpal tunnel syndrome: A placebo-controlled study; [Karpal tünel sendromunda düşük enerjili lazer ve kesikli ultrason tedavi etkinliklerinin karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless}: Plasebo kontrollü bir çali{dotless}şma]
    (2013) Tikiz C.; Duruöz T.; Ünlü Z.; Cerrahoǧlu L.; Yalçinsoy E.
    Objective: To evaluate the effect of low-level laser treatment (LLLT) and pulsed ultrasound (US) treatment in carpal tunnel syndrome (CTS) and to compare the effects of both treatment modalities. Materials and Methods: 60 patients diagnosed with CTS were randomly divided into four groups as US group (group 1), placebo US group (group 2), LLLT group (group 3) and plasebo LLLT group (group 4). Both treatments were applied five days a week for three weeks. Clinical and electrophysiological assessments were performed before and 3, 6 and 12 months after treatment. Pain, hypoesthesia and handgrip strength were evaluated. The Boston Questionnaire was used to assess the severity of symptoms and functional status. Results: 52 patients with 101 hands completed the study. Demographic and electrophysiological parameters were similar in the four groups. Both pulsed US treatment and LLLT were found to provide significant improvements in clinical parameters such as pain, sensory loss, symptom severity score and functional capacity score (p<0.05). No significant beneficial effect was observed in both placebo groups (p<0.05). Evaluations of the electrophysiological parameters showed no significant difference between the groups (p>0.05). In terms of clinical efficacy, pulsed US was found to be superior to LLLT (p<0.05). Conclusion: The two treatment modalities showed significant improvements in subjective clinical symptoms while no significant changes were observed in any electrophysiological parameters. © Turkish Journal of Physical Medicine and Rehabilitation.
  • No Thumbnail Available
    Item
    LIMPRINT study: The Turkish experience
    (Mary Ann Liebert Inc., 2019) Borman P.; Moffatt C.; Murray S.; Yaman A.; Denizli M.; Dalyan M.; Unsal-Delialioǧlu S.; Eyigör S.; Ayhan F.; Çaklt B.D.; Vural S.; Özdemir O.; Kurt E.; Çelik E.C.; Cerrahoǧlu L.; Kepekçi M.; Terzioǧlu F.; Donmez A.A.
    Background: Lymphedema and chronic edema is a major health care problem in both developed and nondeveloped countries The Lymphoedema Impact and Prevelance-International (LIMPRINT) study is an international health service-based study to determine the prevalence and functional impact in adult populations of member countries of the International Lymphoedema Framework (ILF). Methods and Results: A total of 1051 patients from eight centers in Turkey were recruited using the LIMPRINT study protocol. Data were collected using the core and module tools that assess the demographic and clinical properties as well as disability and quality of life (QoL). Most of the Turkish patients were recruited from specialist lymphedema services and were found to be women, housewives, and having secondary lymphedema because of cancer treatment. The duration of lymphedema was commonly <5 years and most of them had International Society of Lymphology (ISL) grade 2 lymphedema. Cellulitis, infection, and wounds were uncommon. The majority of patients did not get any treatment or advice before. Most of the patients had impaired QoL and decreased functionality, but psychological support was neglected. Although most had social health security access to lymphedema centers, nevertheless access seemed difficult because of distance and cost. Conclusion: The study has shown the current status and characteristics of lymphedema patients, treatment conditions, the unmet need for the diagnosis and treatment, as well as burden of the disease in both patients and families in Turkey. National health policies are needed for the prevention, diagnosis, and treatment in Turkey that utilize this informative data. © Pinar Borman et al. 2019; Published by Mary Ann Liebert, Inc. 2019.